HealthCor Management L.P. boosted its stake in Allergan plc (NYSE:AGN) by 14.1% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 825,000 shares of the company’s stock after buying an additional 101,790 shares during the period. Allergan makes up 4.4% of HealthCor Management L.P.’s portfolio, making the stock its 7th largest holding. HealthCor Management L.P. owned 0.25% of Allergan worth $134,954,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Avestar Capital LLC bought a new stake in Allergan in the 4th quarter valued at about $113,000. Focused Wealth Management Inc boosted its holdings in Allergan by 4,444.4% in the 4th quarter. Focused Wealth Management Inc now owns 818 shares of the company’s stock valued at $134,000 after purchasing an additional 800 shares during the period. BB&T Investment Services Inc. boosted its holdings in Allergan by 1,308.2% in the 3rd quarter. BB&T Investment Services Inc. now owns 690 shares of the company’s stock valued at $139,000 after purchasing an additional 641 shares during the period. Acropolis Investment Management LLC bought a new stake in Allergan in the 4th quarter valued at about $153,000. Finally, Field & Main Bank bought a new stake in Allergan in the 4th quarter valued at about $155,000. Institutional investors and hedge funds own 78.40% of the company’s stock.
In other news, insider William Meury sold 58,879 shares of the stock in a transaction on Wednesday, February 14th. The shares were sold at an average price of $160.62, for a total transaction of $9,457,144.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Joseph H. Boccuzi acquired 900 shares of the firm’s stock in a transaction dated Monday, March 5th. The shares were purchased at an average price of $143.42 per share, with a total value of $129,078.00. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 7,200 shares of company stock valued at $1,108,267. 0.36% of the stock is currently owned by corporate insiders.
Allergan (NYSE:AGN) last announced its quarterly earnings results on Tuesday, February 6th. The company reported $4.86 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $4.74 by $0.12. Allergan had a negative net margin of 26.32% and a positive return on equity of 8.43%. The firm had revenue of $4.33 billion during the quarter, compared to analysts’ expectations of $4.28 billion. During the same period in the prior year, the company posted $3.90 EPS. The company’s revenue was up 12.0% on a year-over-year basis. equities research analysts predict that Allergan plc will post 15.58 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 28th. Stockholders of record on Wednesday, February 28th will be given a dividend of $0.72 per share. The ex-dividend date is Tuesday, February 27th. This is a boost from Allergan’s previous quarterly dividend of $0.70. This represents a $2.88 annualized dividend and a dividend yield of 1.83%. Allergan’s dividend payout ratio is -21.46%.
AGN has been the subject of a number of recent research reports. Leerink Swann reissued an “outperform” rating and issued a $237.00 price objective on shares of Allergan in a report on Monday, November 27th. Morgan Stanley raised shares of Allergan from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $171.92 to $200.00 in a report on Wednesday, November 29th. Cantor Fitzgerald set a $191.00 price target on shares of Allergan and gave the stock a “hold” rating in a report on Saturday, December 2nd. TheStreet downgraded shares of Allergan from a “c-” rating to a “d+” rating in a report on Monday, December 4th. Finally, Wells Fargo & Co reaffirmed a “buy” rating on shares of Allergan in a report on Wednesday, December 6th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and fifteen have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $225.03.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.